Rentschler Biopharma

Cell and Gene

Rentschler ATMP was launched by Rentschler Biopharma in February 2021 to provide high-quality drug substance for advanced therapy medicinal products (ATMP).


Rentschler Biopharma is a leading global Contract Development and Manufacturing Organization (CDMO), focused exclusively on client projects. Thanks to our 50 years of proven scientific expertise in biotechnology and our passion for what we do, we count ourselves among the leaders in the industry and make an essential contribution to the global availability of biopharmaceuticals. From our headquarters in Laupheim, Germany, and our site in Milford, MA, USA, we offer end-to-end solutions including biopharmaceutical process development and manufacturing as well as related consulting activities such as project management and regulatory support.


At Rentschler ATMP, our new Center of Excellence, we plan to partner with entrepreneurial players to enable them to transform their ideas into real products with the potential to treat and even cure patients with serious and life-threatening diseases. Rentschler ATMP utilizes a highly flexible business model that addresses the specific needs of each client.

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.